Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn's disease

A chronic inflammatory state is a risk factor for accelerated atherogenesis. The aim of our study was to explore whether Crohn's disease (CD), characterized by recurrent inflammatory episodes, is also associated with accelerated atherogenesis. In 60 CD patients and 122 matched controls, carotid...

Full description

Saved in:
Bibliographic Details
Published in:Journal of lipid research 2007-12, Vol.48 (12), p.2640-2646
Main Authors: van Leuven, Sander I., Hezemans, Rachel, Levels, Johannes H., Snoek, Susan, Stokkers, Pieter C., Hovingh, G. Kees, Kastelein, John J.P., Stroes, Erik S., de Groot, Eric, Hommes, Daan W.
Format: Article
Language:English
Subjects:
Adult
atherosclerosis
Atherosclerosis - etiology
Cardiovascular Diseases - metabolism
Carotid Arteries - diagnostic imaging
Crohn Disease - complications
endothelium
Female
Humans
inflammation
Lipoproteins, HDL - blood
Male
Tunica Intima - diagnostic imaging
Tunica Media - diagnostic imaging
Ultrasonography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A chronic inflammatory state is a risk factor for accelerated atherogenesis. The aim of our study was to explore whether Crohn's disease (CD), characterized by recurrent inflammatory episodes, is also associated with accelerated atherogenesis. In 60 CD patients and 122 matched controls, carotid intima media thickness (IMT), a validated marker for the burden and progression of atherosclerosis, was assessed ultrasonographically. Additional subgroup analyses, including plasma levels of acute phase reactants and HDL protein profiling, were performed in 11 consecutive patients with CD in remission, 10 patients with active CD, and 15 healthy controls. Carotid IMT in patients with CD was increased compared with healthy volunteers: 0.71 (0.17) versus 0.59 (0.14) mm (P < 0.0001), respectively. In the subgroup analysis, HDL levels in controls and patients in remission were identical [(1.45 (0.48) and 1.40 (0.46) mmol/l; P = 0.797], whereas HDL during exacerbation was profoundly reduced: 1.02 (0.33) (P = 0.022). HDL from patients with active CD and CD patients in remission was characterized by a reduced ability to attenuate oxidation compared with controls (P = 0.008 and P = 0.024 respectively). Patients with CD have increased IMT compared with matched controls, indicative of accelerated atherogenesis. The changes during CD exacerbation in terms of HDL concentration and composition imply a role for impaired HDL protection in these patients.
ISSN:0022-2275
1539-7262
DOI:10.1194/jlr.M700176-JLR200